Identification

Name
Azelastine
Accession Number
DB00972  (APRD00813)
Type
Small Molecule
Groups
Approved
Description

Azelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis. Azelastine is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patient over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Structure
Thumb
Synonyms
  • 4-(P-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone
  • Azelastina
  • Azelastinum
Product Ingredients
IngredientUNIICASInChI Key
Azelastine Hydrochloride0L591QR10I79307-93-0YEJAJYAHJQIWNU-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AstelinSpray, metered137 ug/1NasalMeda Pharmaceuticals Ltd1996-11-152016-11-30Us
AstelinSpray, metered137 ug/1NasalPhysicians Total Care, Inc.2004-05-25Not applicableUs
AsteproSpray, metered205.5 ug/1NasalMeda Pharmaceuticals Ltd2009-10-12Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularWallace Pharmaceuticals Inc.2010-10-01Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalA S Medication Solutions2010-07-012017-06-20Us
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalWallace Pharmaceuticals Inc.2015-04-01Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalWallace Pharmaceuticals Inc.2010-07-01Not applicableUs
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalPerrigo New York Inc.2015-04-092018-03-01Us
OptivarSolution / drops.5 mg/mLIntraocularMeda Pharmaceuticals Ltd2000-05-222017-10-11Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AzelastineSpray, metered137 ug/1NasalAscend Laboratories, LLC2017-08-18Not applicableUs
Azelastine HCl NasalSpray205.5 ug/1NasalPerrigo New York Inc.2014-05-09Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/.137mLNasalBreckenridge Pharmaceutical, Inc.2015-07-29Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularSun Pharma Global FZE2010-05-31Not applicableUs
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalApotex Corporation2014-07-07Not applicableUs
Azelastine HydrochlorideSpray137 ug/.137mLNasalUpsher Smith Laboratories2017-03-17Not applicableUs
Azelastine HydrochlorideSpray, metered1 mg/mLNasalAmneal Pharmaceuticals2017-09-05Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalApotex Corporation2010-03-01Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalPhysicians Total Care, Inc.2011-06-28Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalWest Ward Pharmaceutical2014-10-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DymistaAzelastine Hydrochloride (137 mcg) + Fluticasone propionate (50 mcg)Spray, meteredNasalBgp Pharma Ulc2015-03-31Not applicableCanada
DymistaAzelastine Hydrochloride (137 ug/1) + Fluticasone propionate (50 ug/1)Spray, meteredNasalMeda Pharmaceuticals Ltd2012-05-01Not applicableUs
TicalastAzelastine Hydrochloride + Fluticasone propionateKitShoreline Pharmaceuticals, Inc.2016-09-28Not applicableUs
Categories
UNII
ZQI909440X
CAS number
58581-89-8
Weight
Average: 381.898
Monoisotopic: 381.160790112
Chemical Formula
C22H24ClN3O
InChI Key
MBUVEWMHONZEQD-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
IUPAC Name
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)-1,2-dihydrophthalazin-1-one
SMILES
CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O

Pharmacology

Indication

For the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.

Structured Indications
Pharmacodynamics

Azelastine is a relatively selective histamine H1 antagonist, which inhibits the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. It has some affinity to H2 receptors. Based on in vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine. Azelastine may also inhibit the accumulation and degranulation of eosinophils at the site of allergic inflammation.

Mechanism of action

Azelastine competes with histamine for the H1-receptor sites on effector cells and acts as an antagonist by inhibiting the release of histamine and other mediators involved in the allergic response.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Absorption of azelastine following ocular administration was relatively low. Systemic bioavailability is approximately 40% after nasal administration.

Volume of distribution
  • 14.5 L/kg
Protein binding

In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.

Metabolism

Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system, however the exact cytochrome P450 isoenzyme involved has not been determined. The major metabolite, desmethylazelastine, also has H1-receptor antagonist activity.

Route of elimination

Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system.

Half life

Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).

Clearance
  • 0.5 L/h/kg [symptomatic patients]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Azelastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with 5-androstenedione.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
AbciximabAzelastine may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Azelastine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Azelastine.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Azelastine is combined with Acemetacin.Approved
AcenocoumarolAzelastine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Azelastine.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinAzelastine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azelastine.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Azelastine.Approved
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Azelastine is combined with Alaproclate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Azelastine.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Alendronic acid.Approved
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
AliskirenAzelastine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Azelastine.Approved, Investigational
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Azelastine is combined with Aloxiprin.Experimental
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
AlprenololAzelastine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azelastine.Approved, Investigational
AlteplaseAzelastine may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Azelastine may increase the anticoagulant activities of ALX-0081.Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Azelastine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Amcinonide.Approved
AmikacinAzelastine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAzelastine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Azelastine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
AmrubicinAzelastine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideAzelastine may increase the anticoagulant activities of Anagrelide.Approved
AncrodAzelastine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Azelastine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Azelastine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Anisodamine.Investigational
AnistreplaseAzelastine may increase the anticoagulant activities of Anistreplase.Approved
annamycinAzelastine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.Approved
Antithrombin III humanAzelastine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Azelastine is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Azelastine is combined with Apocynin.Investigational
ApramycinAzelastine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Azelastine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinAzelastine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAzelastine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAzelastine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ArmodafinilThe metabolism of Azelastine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololAzelastine may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.Approved, Investigational
ArtemetherThe metabolism of Azelastine can be decreased when combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azelastine resulting in a loss in efficacy.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AstaxanthinAzelastine may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Azelastine is combined with Atamestane.Investigational
AtazanavirThe metabolism of Azelastine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Azelastine.Approved
AtomoxetineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Azelastine is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Azelastine.Approved, Investigational
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational, Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azelastine.Approved
AzithromycinThe metabolism of Azelastine can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BalsalazideAzelastine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit
BatroxobinAzelastine may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminAzelastine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAzelastine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAzelastine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Azelastine.Approved, Investigational
BemiparinAzelastine may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azelastine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Azelastine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azelastine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Azelastine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Benoxaprofen.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Benzylpenicilloyl PolylysineAzelastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azelastine.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Azelastine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Azelastine.Approved, Vet Approved
BetaxololThe metabolism of Azelastine can be decreased when combined with Betaxolol.Approved
BevantololAzelastine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Azelastine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azelastine.Approved, Investigational
BisoprololAzelastine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAzelastine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Azelastine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololAzelastine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Azelastine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Azelastine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Azelastine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BrinaseAzelastine may increase the anticoagulant activities of Brinase.Experimental
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine.Approved
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.Approved, Investigational
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bucillamine.Investigational
BucindololAzelastine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Azelastine is combined with Bufexamac.Experimental
BuflomedilAzelastine may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolAzelastine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Bumadizone.Experimental
BumetanideAzelastine may decrease the diuretic activities of Bumetanide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
BupranololAzelastine may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Azelastine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
ButylphthalideAzelastine may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Azelastine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Azelastine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Azelastine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Azelastine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Azelastine.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azelastine.Experimental
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
CangrelorAzelastine may increase the anticoagulant activities of Cangrelor.Approved
CapecitabineThe metabolism of Azelastine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azelastine.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Azelastine is combined with Carbaspirin calcium.Experimental, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azelastine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Azelastine.Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azelastine.Approved, Vet Approved, Withdrawn
CarteololAzelastine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAzelastine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Azelastine is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Azelastine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololAzelastine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Azelastine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Azelastine.Withdrawn
CertoparinAzelastine may increase the anticoagulant activities of Certoparin.Approved, Investigational
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Azelastine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ChloroquineThe metabolism of Azelastine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Azelastine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azelastine.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CholecalciferolThe metabolism of Azelastine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Azelastine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Azelastine.Approved
CinacalcetThe metabolism of Azelastine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
CinoxacinAzelastine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Azelastine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Azelastine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Azelastine.Approved
Citric AcidAzelastine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Azelastine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Azelastine.Approved, Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonixin.Approved
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Azelastine.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azelastine.Vet Approved
CloranololAzelastine may decrease the antihypertensive activities of Cloranolol.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
CloricromenAzelastine may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneAzelastine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
ClotrimazoleThe metabolism of Azelastine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CobicistatThe serum concentration of Azelastine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Azelastine.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Azelastine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Azelastine is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Azelastine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Azelastine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Azelastine.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Azelastine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Azelastine can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Azelastine is combined with Curcumin.Investigational
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Azelastine.Experimental
CyclosporineAzelastine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Cyproterone acetateThe serum concentration of Azelastine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Azelastine is combined with D-Limonene.Investigational
Dabigatran etexilateAzelastine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Azelastine.Approved
DalteparinAzelastine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAzelastine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapoxetine.Investigational
DarexabanAzelastine may increase the anticoagulant activities of Darexaban.Investigational
DarifenacinThe metabolism of Azelastine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Azelastine can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Azelastine.Approved, Investigational
DaunorubicinAzelastine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Azelastine.Approved, Investigational
DeferasiroxThe serum concentration of Azelastine can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideAzelastine may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Azelastine.Experimental
DelavirdineThe metabolism of Azelastine can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Deoxycholic Acid.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
dersalazineThe risk or severity of adverse effects can be increased when Azelastine is combined with dersalazine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DesirudinAzelastine may increase the anticoagulant activities of Desirudin.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.Approved
DesmoteplaseAzelastine may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azelastine.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DextranAzelastine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Azelastine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Azelastine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Azelastine may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
DibekacinAzelastine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azelastine.Approved, Vet Approved
DicoumarolAzelastine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Azelastine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azelastine.Approved, Investigational
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Azelastine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Azelastine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Azelastine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azelastine.Approved
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Azelastine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Azelastine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Azelastine.Experimental
DihydroergotamineThe metabolism of Azelastine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DihydrostreptomycinAzelastine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Azelastine.Illicit
DiltiazemThe metabolism of Azelastine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Azelastine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azelastine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azelastine.Approved
DiphenadioneAzelastine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Azelastine.Approved
DitazoleAzelastine may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
DosulepinThe metabolism of Azelastine can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Azelastine.Approved, Investigational
DoxorubicinAzelastine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Azelastine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DronedaroneThe metabolism of Azelastine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DrospirenoneAzelastine may increase the hyperkalemic activities of Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
Drotrecogin alfaAzelastine may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Droxicam.Approved
DuloxetineThe metabolism of Azelastine can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Azelastine is combined with Duvelisib.Investigational
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
E-6201The risk or severity of adverse effects can be increased when Azelastine is combined with E-6201.Investigational
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
Edetic AcidAzelastine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Azelastine.Approved
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Azelastine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Azelastine.Approved, Investigational
EliglustatThe metabolism of Azelastine can be decreased when combined with Eliglustat.Approved
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azelastine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azelastine.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Azelastine.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
EnoxacinAzelastine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAzelastine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Azelastine.Experimental
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
EnzalutamideThe serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.Approved
EpanololAzelastine may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Azelastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Epirizole.Approved
EpirubicinAzelastine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAzelastine may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinAzelastine may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineAzelastine may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Azelastine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.Approved
EptifibatideAzelastine may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Azelastine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Azelastine is combined with Equilin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azelastine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Azelastine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Azelastine.Approved, Investigational
ErythromycinThe metabolism of Azelastine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Azelastine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololAzelastine may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Azelastine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Azelastine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Azelastine is combined with Estrone sulfate.Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Etacrynic acidAzelastine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.Approved, Investigational
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azelastine.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Ethyl biscoumacetateAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Etidronic acid.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational, Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Etofenamate.Approved, Investigational
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Azelastine.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Vet Approved
EtravirineThe metabolism of Azelastine can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Azelastine is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Azelastine.Approved
exisulindThe risk or severity of adverse effects can be increased when Azelastine is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Azelastine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FelbinacThe risk or severity of adverse effects can be increased when Azelastine is combined with Felbinac.Experimental
FelodipineThe metabolism of Azelastine can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenbufen.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azelastine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azelastine.Vet Approved
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Azelastine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Feprazone.Experimental
Ferulic acidAzelastine may increase the anticoagulant activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FibrinolysinAzelastine may increase the anticoagulant activities of Fibrinolysin.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Azelastine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Azelastine.Approved, Investigational
FleroxacinAzelastine may increase the neuroexcitatory activities of Fleroxacin.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azelastine.Approved, Withdrawn
FloxuridineThe metabolism of Azelastine can be decreased when combined with Floxuridine.Approved
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
fluasteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with fluasterone.Investigational
FluconazoleThe metabolism of Azelastine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fludrocortisone.Approved
FluindioneAzelastine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAzelastine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Azelastine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azelastine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Flurandrenolide.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azelastine.Approved, Investigational
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Azelastine.Approved
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FluvastatinThe metabolism of Azelastine can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azelastine.Approved, Nutraceutical, Vet Approved
FondaparinuxAzelastine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAzelastine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azelastine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Azelastine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Azelastine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Azelastine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
FramycetinAzelastine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAzelastine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Azelastine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
GabexateAzelastine may increase the anticoagulant activities of Gabexate.Investigational
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
GarenoxacinAzelastine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAzelastine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Azelastine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Azelastine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azelastine.Approved, Withdrawn
GemfibrozilThe metabolism of Azelastine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAzelastine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAzelastine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAzelastine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAzelastine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepefrineGepefrine may decrease the sedative activities of Azelastine.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Azelastine.Approved
GlucosamineGlucosamine may increase the antiplatelet activities of Azelastine.Approved
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
GPX-150Azelastine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Azelastine.Approved
GrepafloxacinAzelastine may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Azelastine is combined with Guacetisal.Experimental
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Azelastine is combined with Haloperidol.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Azelastine is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Azelastine is combined with Hemoglobin crosfumaril.Experimental
HeparinAzelastine may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
HigenamineAzelastine may increase the anticoagulant activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.Approved, Investigational
HydralazineAzelastine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
HydrocodoneAzelastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Azelastine.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azelastine.Approved, Investigational
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Azelastine.Approved
HydroxytyrosolAzelastine may increase the antiplatelet activities of Hydroxytyrosol.Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Hygromycin BAzelastine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Azelastine.Approved
IbudilastAzelastine may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Azelastine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Azelastine is combined with Icatibant.Approved
Icosapent ethylAzelastine may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinAzelastine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Azelastine can be increased when it is combined with Idelalisib.Approved
IdraparinuxAzelastine may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilAzelastine may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanAzelastine may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
IloprostIloprost may increase the antiplatelet activities of Azelastine.Approved, Investigational
ImatinibThe metabolism of Azelastine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Azelastine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Imidazole salicylate.Experimental
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Azelastine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.Approved
IndenololAzelastine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Azelastine can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
IndobufenAzelastine may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Azelastine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Indoprofen.Withdrawn
INNO-206Azelastine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Azelastine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Azelastine.Approved
IrbesartanThe metabolism of Azelastine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Azelastine.Approved, Investigational
IsavuconazoniumThe metabolism of Azelastine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinAzelastine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
IsoniazidThe metabolism of Azelastine can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Azelastine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Azelastine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Azelastine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Azelastine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Azelastine.Approved, Vet Approved
KanamycinAzelastine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Kebuzone.Experimental
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
KetanserinAzelastine may increase the antiplatelet activities of Ketanserin.Investigational
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
KetoconazoleThe metabolism of Azelastine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azelastine.Approved
LabetalolAzelastine may decrease the antihypertensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Azelastine.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LandiololAzelastine may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Azelastine.Approved, Investigational
LapatinibThe metabolism of Azelastine can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azelastine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Azelastine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Azelastine.Approved
LeflunomideThe metabolism of Azelastine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Azelastine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Azelastine.Approved
LepirudinAzelastine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAzelastine may increase the anticoagulant activities of Letaxaban.Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LevobunololAzelastine may decrease the antihypertensive activities of Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevofloxacinAzelastine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Azelastine.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Azelastine.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Azelastine.Approved
LinsidomineAzelastine may increase the antiplatelet activities of Linsidomine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Azelastine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azelastine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lisofylline.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Azelastine.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Azelastine.Approved
LobeglitazoneThe metabolism of Azelastine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit
LonazolacThe risk or severity of adverse effects can be increased when Azelastine is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Azelastine.Approved
LopinavirThe metabolism of Azelastine can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LorcaserinThe metabolism of Azelastine can be decreased when combined with Lorcaserin.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.Approved, Investigational
LosartanThe serum concentration of Losartan can be increased when it is combined with Azelastine.Approved
LovastatinThe metabolism of Azelastine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azelastine.Approved, Investigational
LuliconazoleThe serum concentration of Azelastine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Azelastine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Azelastine can be decreased when combined with Lumefantrine.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Azelastine.Vet Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Azelastine.Illicit, Investigational, Withdrawn
Magnesium salicylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ManidipineThe metabolism of Azelastine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Azelastine.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azelastine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Azelastine is combined with ME-609.Investigational
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.Approved, Vet Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azelastine.Approved
MelagatranAzelastine may increase the anticoagulant activities of Melagatran.Experimental
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Azelastine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azelastine.Approved, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Azelastine.Investigational
MephentermineMephentermine may decrease the sedative activities of Azelastine.Approved
MepindololAzelastine may decrease the antihypertensive activities of Mepindolol.Experimental
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mesalazine.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.Investigational, Withdrawn
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Azelastine.Experimental
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azelastine.Approved
MethotrimeprazineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Azelastine.Experimental
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Azelastine.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Azelastine.Approved
MetipranololAzelastine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Azelastine.Approved, Investigational
MetrizamideAzelastine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetyrosineAzelastine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Azelastine.Experimental
MexiletineThe metabolism of Azelastine can be decreased when combined with Mexiletine.Approved
MicronomicinAzelastine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Azelastine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Azelastine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Azelastine is combined with Milnacipran.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Azelastine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Azelastine.Approved
MirtazapineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azelastine.Approved
MitotaneThe serum concentration of Azelastine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Azelastine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Azelastine.Experimental, Illicit
MoclobemideThe metabolism of Azelastine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Azelastine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Mofebutazone.Experimental
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azelastine.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azelastine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Azelastine.Approved
NadroparinAzelastine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAzelastine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelastine.Approved
NaftopidilAzelastine may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Nalidixic AcidAzelastine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Azelastine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Azelastine.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azelastine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Azelastine is combined with NCX 1022.Investigational
NeamineAzelastine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Azelastine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Azelastine can be decreased when combined with Nelfinavir.Approved
NemonoxacinAzelastine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAzelastine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Nepafenac.Approved
NetilmicinAzelastine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Azelastine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Azelastine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Azelastine can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Azelastine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Azelastine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Azelastine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Azelastine.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitroaspirin.Investigational
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Azelastine.Approved
NorfloxacinAzelastine may increase the neuroexcitatory activities of Norfloxacin.Approved
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Azelastine.Investigational
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
OlaparibThe metabolism of Azelastine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azelastine.Approved, Investigational
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OlsalazineAzelastine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azelastine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Azelastine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Azelastine.Approved, Nutraceutical
OmeprazoleThe metabolism of Azelastine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Azelastine is combined with Orgotein.Vet Approved
OrphenadrineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
OsimertinibThe serum concentration of Azelastine can be increased when it is combined with Osimertinib.Approved
OtamixabanAzelastine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxethazaineOxethazaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Oxolinic acidAzelastine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.Approved, Withdrawn
OzagrelAzelastine may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Azelastine.Approved, Vet Approved
PalbociclibThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PamidronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Azelastine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Azelastine can be decreased when combined with Pantoprazole.Approved
ParaldehydeAzelastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Paramethasone.Approved
ParnaparinAzelastine may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinAzelastine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Azelastine can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.Approved
PazufloxacinAzelastine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAzelastine may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAzelastine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Azelastine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Azelastine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azelastine.Approved
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
PhenindioneAzelastine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PhenprocoumonAzelastine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Azelastine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azelastine.Approved, Vet Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Azelastine.Approved
PicotamideAzelastine may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.Approved, Investigational
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PindololAzelastine may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Azelastine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Pipemidic acidAzelastine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
PirarubicinAzelastine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAzelastine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.Approved, Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
Piromidic acidAzelastine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Azelastine.Approved
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PlazomicinAzelastine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAzelastine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azelastine.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Azelastine.Approved
PosaconazoleThe metabolism of Azelastine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololAzelastine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azelastine.Approved
PramipexoleAzelastine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Azelastine is combined with Prasterone sulfate.Investigational
PrasugrelAzelastine may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Azelastine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Azelastine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Azelastine is combined with Prednicarbate.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Azelastine.Approved, Vet Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregnenolone.Experimental, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ProbenecidThe serum concentration of Azelastine can be increased when it is combined with Probenecid.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Azelastine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Azelastine is combined with Proglumetacin.Experimental
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Azelastine is combined with Propacetamol.Approved, Investigational
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Azelastine.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azelastine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azelastine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Azelastine.Vet Approved
Protein CAzelastine may increase the anticoagulant activities of Protein C.Approved
Protein S humanAzelastine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAzelastine may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Azelastine.Approved
PrulifloxacinAzelastine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Azelastine.Approved
PTC299The risk or severity of adverse effects can be increased when Azelastine is combined with PTC299.Investigational
PuromycinAzelastine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Azelastine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azelastine.Approved
QuinidineThe metabolism of Azelastine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Azelastine.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
RabeprazoleThe metabolism of Azelastine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
RamatrobanAzelastine may increase the antiplatelet activities of Ramatroban.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Azelastine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Azelastine.Approved, Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.Approved
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseAzelastine may increase the anticoagulant activities of Reteplase.Approved
ReviparinAzelastine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAzelastine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelAzelastine may increase the antiplatelet activities of Ridogrel.Approved
RifabutinThe metabolism of Azelastine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Azelastine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Azelastine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Azelastine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
RitobegronRitobegron may decrease the sedative activities of Azelastine.Investigational
RitonavirThe metabolism of Azelastine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanAzelastine may increase the anticoagulant activities of Rivaroxaban.Approved
RolapitantThe metabolism of Azelastine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Azelastine.Approved, Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
RopiniroleAzelastine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
RosiglitazoneThe metabolism of Azelastine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinAzelastine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Azelastine.Approved
RotigotineAzelastine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Azelastine.Approved
RufloxacinAzelastine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAzelastine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Azelastine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.Experimental
SaquinavirThe metabolism of Azelastine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azelastine.Investigational
SarpogrelateAzelastine may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseAzelastine may increase the anticoagulant activities of Saruplase.Experimental
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Azelastine.Approved
SemapimodThe risk or severity of adverse effects can be increased when Azelastine is combined with Semapimod.Investigational
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Azelastine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Azelastine is combined with Serrapeptase.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Azelastine can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
SildenafilThe metabolism of Azelastine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Azelastine.Approved
SiltuximabThe serum concentration of Azelastine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Azelastine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Azelastine.Approved
SisomicinAzelastine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAzelastine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Azelastine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Azelastine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Azelastine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Azelastine.Approved, Investigational
SotalolAzelastine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAzelastine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAzelastine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinAzelastine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Azelastine.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azelastine.Approved
SpironolactoneAzelastine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Azelastine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Azelastine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Azelastine can be increased when it is combined with Stiripentol.Approved
StreptokinaseAzelastine may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinAzelastine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAzelastine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
SulfadiazineThe metabolism of Azelastine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azelastine.Approved
SulfisoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azelastine.Approved
SulodexideAzelastine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Azelastine.Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.Approved, Withdrawn
SuvorexantAzelastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SuxibuzoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Suxibuzone.Experimental
TacrolimusAzelastine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Azelastine.Approved
TalinololAzelastine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azelastine.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Azelastine.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Azelastine is combined with Tarenflurbil.Investigational
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azelastine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Azelastine.Experimental
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Technetium Tc-99m medronate.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Azelastine.Approved
TelaprevirThe metabolism of Azelastine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Azelastine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.Approved, Investigational
TemafloxacinAzelastine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azelastine.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.Approved
TenecteplaseAzelastine may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Azelastine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Azelastine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azelastine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Azelastine is combined with Tepoxalin.Vet Approved
TerbinafineThe metabolism of Azelastine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Azelastine.Experimental
TeriflunomideThe serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.Approved
TertatololAzelastine may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneAzelastine may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
ThalidomideAzelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Azelastine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Azelastine.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Azelastine.Approved
TiclopidineThe metabolism of Azelastine can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
Tiludronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Azelastine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tinoridine.Investigational
TinzaparinAzelastine may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolAzelastine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Azelastine.Approved, Investigational
TirofibanAzelastine may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Azelastine is combined with Tixocortol.Approved
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TobramycinAzelastine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Azelastine can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Azelastine.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TopiroxostatThe metabolism of Azelastine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Azelastine.Approved, Investigational
TorasemideAzelastine may decrease the diuretic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Azelastine.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azelastine.Approved
TranilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TrapidilAzelastine may increase the antiplatelet activities of Trapidil.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Azelastine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAzelastine may decrease the antihypertensive activities of Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TribenosideThe risk or severity of adverse effects can be increased when Azelastine is combined with Tribenoside.Experimental
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
TriflusalAzelastine may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimethoprimThe metabolism of Azelastine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Triptolide.Investigational
TrovafloxacinAzelastine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAzelastine may increase the anticoagulant activities of Troxerutin.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Azelastine.Approved, Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Azelastine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Azelastine.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azelastine.Approved
UrokinaseAzelastine may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ValrubicinAzelastine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Azelastine can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azelastine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Azelastine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Azelastine.Approved
VemurafenibThe serum concentration of Azelastine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Azelastine.Approved
VenlafaxineThe metabolism of Azelastine can be decreased when combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
VerapamilThe metabolism of Azelastine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Azelastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.Approved, Investigational
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Azelastine.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Azelastine.Approved, Nutraceutical, Vet Approved
VorapaxarAzelastine may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Azelastine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Azelastine.Approved
WarfarinAzelastine may increase the anticoagulant activities of Warfarin.Approved
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
XimelagatranAzelastine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
ZafirlukastThe metabolism of Azelastine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen.Approved, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Azelastine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azelastine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Azelastine.Experimental
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Zoledronic acid.Approved
ZolpidemAzelastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.Withdrawn
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Zoptarelin doxorubicinAzelastine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAzelastine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ZucapsaicinThe metabolism of Azelastine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Yutaka Morita, Noritoshi Koyama, Shigemitsu Ohsawa, "Methods employing stable preparation containing azelastine hydrochloride." U.S. Patent US6117864, issued December, 1990.

US6117864
General References
  1. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282]
  2. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160]
External Links
Human Metabolome Database
HMDB15107
KEGG Compound
C07768
PubChem Compound
2267
PubChem Substance
46507582
ChemSpider
2180
BindingDB
50341448
ChEBI
2950
ChEMBL
CHEMBL639
Therapeutic Targets Database
DNC000270
PharmGKB
PA448517
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Azelastine
ATC Codes
R01AC03 — AzelastineR06AX19 — AzelastineS01GX07 — Azelastine
FDA label
Download (17.5 KB)
MSDS
Download (36.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAllergic Rhinitis (AR)2
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Seasonal1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2Unknown StatusTreatmentSeasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentChronic Allergic Rhinitis / Nonallergic Rhinitis1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)4
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)10
3Unknown StatusNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4Not Yet RecruitingTreatmentAllergic Rhinitis (AR) / Allergies / Asthma, Allergic1
4RecruitingBasic ScienceAllergic Rhinitis (AR)1
4RecruitingTreatmentAllergic Rhinitis (AR) / House Dust Mite Allergy1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
Not AvailableRecruitingSupportive CareBioavailability Study1

Pharmacoeconomics

Manufacturers
  • Apotex inc richmond hill
  • Sun pharma global fze
  • Meda pharmaceuticals inc
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Apotex inc
  • Meda pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Spray, meteredNasal137 ug/1
SprayNasal205.5 ug/1
Solution / dropsOphthalmic.5 mg/mL
SprayNasal137 ug/.137mL
Spray, meteredNasal1 mg/mL
Spray, meteredNasal137 ug/.137mL
Spray, meteredNasal205.5 ug/1
Spray, meteredNasal
Solution / dropsIntraocular.5 mg/mL
Kit
Prices
Unit descriptionCostUnit
Optivar 0.05% Solution 6ml Bottle120.26USD bottle
Astelin 137 mcg/spray Solution 30ml Bottle117.27USD bottle
Azelastine HCl 0.05% Solution 6ml Bottle108.23USD bottle
Optivar 0.05% drops19.27USD ml
Azelastine hcl 0.05% drops17.35USD ml
Astelin 137 mcg nasal spray3.71USD ml
Astepro 137 mcg nasal spray3.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164194No1994-05-012011-05-01Us
US8518919No2005-11-222025-11-22Us
US8071073No2008-06-042028-06-04Us
US8163723Yes2004-02-292024-02-29Us
US9259428Yes2003-12-132023-12-13Us
US8168620Yes2006-08-242026-08-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)225 °C (hydrochloride salt)Not Available
water solubilitySparingly soluble (hydrochloride salt)Not Available
logP4.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0092 mg/mLALOGPS
logP3.81ALOGPS
logP4.04ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.91 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity110.52 m3·mol-1ChemAxon
Polarizability41.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.7034
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.9563
Renal organic cation transporterInhibitor0.6812
CYP450 2C9 substrateNon-substrate0.7501
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.8204
CYP450 1A2 substrateInhibitor0.6371
CYP450 2C9 inhibitorNon-inhibitor0.8114
CYP450 2D6 inhibitorNon-inhibitor0.568
CYP450 2C19 inhibitorNon-inhibitor0.6934
CYP450 3A4 inhibitorNon-inhibitor0.5902
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7266
Ames testNon AMES toxic0.6567
CarcinogenicityNon-carcinogens0.878
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0597 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7885
hERG inhibition (predictor II)Inhibitor0.7391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0219000000-689aed0dccf673820d4e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03e9-2908000000-3d19ebb91515adce237b

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalazinones. These are compounds containing a phthalazine bearing a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Phthalazinones
Alternative Parents
Pyridazinones / Chlorobenzenes / Azepanes / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Phthalazinone / Azepane / Chlorobenzene / Halobenzene / Pyridazinone / Monocyclic benzene moiety / Aryl chloride / Pyridazine / Aryl halide / Benzenoid
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, monochlorobenzenes, phthalazines (CHEBI:2950)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Casale TB: The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989 Apr;83(4):771-6. [PubMed:2540229]
  2. Conde Hernandez DJ, Palma Aqilar JL, Delgado Romero J: Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin. 1995;13(6):299-304. [PubMed:8829888]
  3. Antepara I, Jauregui I, Basomba A, Cadahia A, Feo F, Garcia JJ, Gonzalo MA, Luna I, Rubio M, Vazquez M: [Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis]. Allergol Immunopathol (Madr). 1998 Jan-Feb;26(1):9-16. [PubMed:9585822]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282]
  6. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160]
  7. Golden SJ, Craig TJ: Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. J Am Osteopath Assoc. 1999 Jul;99(7 Suppl):S7-12. [PubMed:10478514]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
2. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118]
  2. Hu YP, Robert J: Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol. 1995 Jul 17;50(2):169-75. [PubMed:7632160]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:45